MacroGenics, Inc. — Q1 2015 Form 10-Q
Business context and period. This biopharmaceutical company develops antibody-based therapies, primarily for cancer, as well as autoimmune disorders and infectious diseases. This unaudited report covers the three months ended March 31, 2015; comparisons are with Q1 2014 unless otherwise noted. The company reported no product sales.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Total revenue | $71.3 million | $14.7 million; up 385% |
| Collaborative research revenue | $71.2 million | $14.4 million; up $56.7 million |
| Operating expenses | $26.1 million | $17.8 million |
| Operating income (loss) | $45.1 million | $(3.1) million |
| Net income (loss) | $45.1 million | $(3.1) million |
| Basic / diluted EPS | $1.53 / $1.42 | $(0.12) / $(0.12) |
| Operating cash flow | $43.6 million | $5.9 million |
| Cash and cash equivalents at quarter-end | $263.1 million | $157.6 million at Dec. 31, 2014 |
Operating margin was approximately 63% in Q1 2015, versus approximately negative 21% in Q1 2014, calculated from reported revenue and operating income (loss). Research and development expense rose 47% to $21.5 million, mainly for margetuximab Phase 3 preparations, MGD010 clinical preparations, and MGD009 IND preparation. General and administrative expense increased 42% to $4.7 million, primarily on higher stock compensation, labor, and IT costs.
Investing cash outflow was $1.0 million, primarily for lab equipment. Financing cash inflow was $62.9 million, including $62.7 million reported from the JJDC stock transaction and stock-option exercises. Cash increased $105.5 million during the quarter. Total assets were $278.1 million and total liabilities $47.1 million at March 31. The balance sheet lists no borrowings; liabilities included deferred revenue, lease-exit obligations, and other operating liabilities. Current assets were $268.5 million versus current liabilities of $24.1 million.
Material changes and notable items
- Q1 revenue and profit were driven chiefly by collaboration accounting: MacroGenics recognized $62.3 million under the Janssen MGD011 arrangement after submitting the IND, and approximately $4.3 million under Takeda, including a $3.0 million MGD010 Phase 1a milestone.
- The Janssen collaboration and related JJDC equity investment closed in January. Janssen paid a $50.0 million upfront fee; JJDC purchased 1,923,077 shares for $75.0 million. The filing allocated $62.3 million of arrangement consideration to the license and preclinical work, recognized in Q1, and $62.7 million to equity. The company may receive up to $575 million in additional Janssen clinical, regulatory, and commercialization milestones, plus royalties if commercialized.
- Share count increased to 30.0 million at March 31 from 28.0 million at year-end; 30,047,629 shares were outstanding on April 30.
- Deferred revenue totaled approximately $26.8 million at quarter-end. The company’s reported profit therefore reflects collaboration revenue recognition, not product-sale revenue or a recurring product business.
Outlook, risks, and contingencies
Management said existing cash and anticipated collaboration payments were expected to fund operations into 2018, assuming programs advance as contemplated. It expected R&D spending to increase as clinical and preclinical programs progress. No formal revenue or earnings guidance was provided. Planned activities included starting a potential registration Phase 3 margetuximab trial in metastatic breast cancer, advancing clinical trials for MGD006 and MGD007, and beginning human studies of MGD011 in 2015; the company also expected to submit an IND for MGD009 in 2015.
Funding remains dependent in part on uncertain milestone achievement, collaborator payments, and future development outcomes. The company had not generated product revenue and cautioned that product approval and commercialization were uncertain. Other disclosed risks include clinical-trial and regulatory outcomes, competition, intellectual property, litigation, international operations, and the ability to secure collaborations and financing. A legacy Raven acquisition agreement could require a $5.0 million payment if a qualifying Cancer Stem Cell Program Phase 2 trial begins by July 15, 2018, as well as other contingent consideration if specified conditions are met. No additional contingent amounts were recorded in Q1. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- How much of the sharp increase in reported revenue and earnings is attributable to one-time or milestone-related collaboration recognition, and how much is expected to recur.
- Whether clinical programs meet milestones and timelines, particularly margetuximab Phase 3, MGD011 clinical initiation, and the planned MGD009 IND.
- Whether collaboration payments and milestones materialize as assumed in management’s conditional runway estimate through 2018.
- Potential future dilution from equity issuance and stock-based compensation, and any contingent Raven-related payments.
- Whether the substantial cash balance is sufficient as R&D and clinical-trial spending rises.